Core Viewpoint - The company reported significant growth in its mid-term performance, showcasing a strong recovery and positive cash flow, driven by its dual business model in preclinical products and antibody discovery [1] Financial Performance - The company's revenue for the six months ending June 30, 2025, was RMB 621 million, representing a year-on-year increase of 51.3% [1] - The profit attributable to equity shareholders was RMB 47.99 million, a turnaround from a loss of RMB 50.67 million in the same period last year, with basic earnings per share at RMB 0.12 [1] - Net cash inflow from operating activities was RMB 203 million, with a net cash flow of RMB 33.3 million, indicating a complete turnaround in overall cash flow [1] Business Model and Strategy - The company has established a dual-driven business ecosystem focusing on preclinical products and services, as well as antibody discovery, which enhances growth through technological synergy and resource collaboration [1] - The preclinical products and services segment, centered on innovative animal model sales, generated revenue of RMB 458 million in the first half of 2025, marking a 56.9% increase compared to the same period last year, while maintaining a high gross margin of approximately 70% [1]
百奥赛图-B(02315.HK)上半年扭亏为盈至4799.9万元 营收大幅增长51.3%至6.21亿元